Search for: "Deas v. Deas"
Results 41 - 60
of 817
Sort by Relevance
|
Sort by Date
9 Jun 2023, 11:38 am
June 2, 2023Smolen v. [read post]
21 May 2023, 1:37 pm
v Walton et.al. [read post]
17 May 2023, 8:38 am
This authority may extend to writing prescriptions for drugs that the Illinois Controlled Substances Act has grouped in Schedule II, III, IV, or V. [read post]
16 May 2023, 1:41 pm
Schedule I has the most severe sentencing range, with Schedule V the least. [read post]
7 May 2023, 6:41 pm
See Perez v. [read post]
16 Apr 2023, 7:41 am
Michigan v. [read post]
7 Apr 2023, 6:43 am
Jordan v. [read post]
5 Apr 2023, 4:05 am
In Iowaska Church of Healing v. [read post]
31 Mar 2023, 9:31 am
Here, a telehealth practitioner may prescribe up to a 30-day supply of a schedule III-V non-narcotic controlled medication. [read post]
28 Mar 2023, 6:00 pm
Vanda Pharm. v. [read post]
27 Mar 2023, 10:25 am
The Supreme Court held in Bruton v. [read post]
10 Mar 2023, 7:08 am
Stevens v. [read post]
7 Mar 2023, 7:14 am
Notably, the proposed rules also give DEA-registered practitioners who have relied on the DEA’s emergency waiver—which, since January 2020, has allowed practitioners to prescribe Schedules II-V controlled substances without conducting a prior in-person medical evaluation of the patient—up to 180 days to come into compliance with the new in-person evaluation requirements that would be implemented in the final regulations. [read post]
2 Mar 2023, 9:05 pm
Supreme Court’s decision in Dobbs v. [read post]
1 Mar 2023, 8:00 am
Under the proposed rules, where a practitioner and patient established a telemedicine relationship during the PHE and where the practitioner, relying on the DEA waiver, prescribed Schedules II-V controlled substances to the patient without conducting an in-person medical evaluation of the patient, practitioners would be given 180-days to come into compliance with in-person evaluation requirements. [read post]
27 Feb 2023, 3:54 pm
The only schedule III-V narcotic drug that is currently approved by the FDA for OUD treatment is buprenorphine. [read post]
27 Feb 2023, 3:01 am
Aims Institute, PLLC, v. [read post]
12 Feb 2023, 8:09 am
See Page v. [read post]
25 Jan 2023, 9:05 pm
United States v. [read post]
17 Jan 2023, 10:17 am
The deliberate indifference claim recognized in Carlson v. [read post]
